There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
| Orders | Qty | Bid |
|---|---|---|
| 2 | 48 | 1416.3 |
| 2 | 27 | 1416.1 |
| 11 | 163 | 1416 |
| 3 | 75 | 1415.7 |
| 3 | 180 | 1415.6 |
| Ask | Qty | Orders |
|---|---|---|
| 1416.5 | 2 | 3 |
| 1416.8 | 1 | 12 |
| 1417.2 | 4 | 43 |
| 1417.3 | 2 | 3 |
| 1417.4 | 1 | 23 |
Annual Revenue,rose 6.7%, in the last year to ₹3,074 Cr. Its sector's average revenue growth for the last fiscal year was 10.62%.Annual Net Profit,rose 89.85% in the last year to ₹47 Cr. Its sector's average net profit growth for the last fiscal year was 36.73%.Interest Coverage Ratio,is 1.79, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).
Wockhardt Limited operates as a worldwide pharmaceutical and biotech organization which maintains operations throughout the UK and Switzerland and Ireland and Russia and multiple additional countries. The company operates manufacturing facilities in India and the UK and Ireland and Dubai while maintaining substantial operations in Europe and India. The Company operates from D-4 M.I.D.C. Chikalthana in Chhatrapati Sambhajinagar Maharashtra 431006 (corporate office: Wockhardt Towers, BKC, Mumbai) where its equity shares are listed on BSE and NSE. The company received its incorporation on July 8th 1999.
Wockhardt dedicates 80% of its operations to pharmaceutical manufacturing and medicinal chemical and botanical product production while conducting 20% of its business through wholesale trading activities. The main business activity of Wockhardt falls under “Manufacture of pharmaceuticals, medicinal and chemical products” which corresponds to NIC 210.
The company operates through 8 Indian plants and 2 offices and 4 international plants and 17 international offices which provide services to 28 Indian states and 47 international countries.
The Group operated through 7 subsidiaries according to Form AOC-1 during March 31 2025.
Wockhardt continues to concentrate on antibiotic research through its development of six new antibiotics which target antibiotic-resistant bacteria. The Company has developed an extensive intellectual property portfolio through its patent filing of 3,273 cumulative applications and its receipt of 848 granted patents as of March 31 2025.
The revenue from operations originated from domestic operations at 22% while international operations generated 78% of total revenue. The company reports its regional distribution as follows:
Approval from Indian Drug Authority: The Indian drug authority approved Miqnaf (Nafithromycin) as a new-generation oral antibiotic for treating Community Acquired Bacterial Pneumonia (CABP). The Company submitted its homegrown fast-acting insulin analog Aspart injection (ASPARAPID) to the Drugs Controller General of India while it develops multiple insulin analogs and GLP-1 agonists.
US FDA Grant: The US FDA granted WCK 6777 Fast Track designation and the US National Institutes of Health conducted a Phase I study that reached successful completion.
Portfolio Expansion: Wockhardt expanded its intellectual property portfolio through the filing of 3,273 cumulative patents and the granting of 848 patents during the period ending March 31 2025.
Product Launch: Wockhardt UK and Ireland launched six new products each throughout the year.
The Company issued Rs 1,000 crore through a Qualified Institutions Placement (QIP) to fund capital expenditures and research and development and growth initiatives and debt reduction.
Entry into vaccine market: Wockhardt established its intention to enter the vaccine market with COVID-19 vaccines and develop integrated drug substance and product manufacturing capabilities.
Wockhardt operates as a worldwide pharmaceutical and biotechnology organization which produces pharmaceuticals and trades them while maintaining its main business activities in Europe and India. The company operates research and manufacturing facilities in India and the UK and maintains manufacturing sites in Ireland and Dubai.
The international business segment generates 78% of total revenue while domestic operations produce 22%. The reported regional distribution shows that the UK generated 39% of revenue and the EU produced 12% and the US produced 3%.
The Group maintained 7 subsidiaries throughout March 31 2025. The company operates in 28 Indian states while delivering services to 47 countries across the world.
